TEHRAN (ANA)- The ‘polyclonal antibodies’ which are widely used in disease diagnosis and treatment, detection and removal of environmental pollutants, control of pathogens and purification of protein molecules, were produced by Iranian researchers.
Ibn Sina (Avicenna) Research Institute of New Technologies of Biological Sciences affiliated to the Academic Center for Education, Culture and Research has grown into one of the main producers of this product in Iran.
Jafar Mahmoudian, a faculty member of Ibn Sina Research Institute and the director of the project, said that the main goal of the polyclonal antibody production project is to provide the antibodies needed by companies active in the field of IVD.
“In general, the process of polyclonal antibody production starts with antigen preparation. The next step is to choose animal species. Then, the adjuvant is selected and prepared, and the injection protocol is performed. The final steps include monitoring the antibody response and collecting it,” he added.
“The most important advantage of this plan is that companies in the field of IVD and kit making do not need to import polyclonal antibodies, and currently Ibn Sina Research Institute is considered as one of the main producers of polyclonal antibodies for companies active in this field,” Mahmoudian said.
In a relevant development late last year, an Iranian company based in Isfahan Science and Research Town had also succeeded in production of milk enriched with antibodies which creates immunity against viral diseases, including Covid-19, and is effective in their treatment.
“Several decades of experience in research and teaching in the field of common viral diseases and working in the specialized laboratories of the European Union states gave us the opportunity to develop a product to increase immunity and treat certain viral and bacterial diseases,” said Hassan Nili Ahmadabadi, the managing-director of the company.
“Using this product in the digestive system inactivates the virus or bacteria against which the antibody has been produced. Given the positive results of tests on this product, we managed to obtain an industrial production license from the Iran Food and Drug Administration (IFDA). This antigen and pathogen resistant milk is considered a completely new product,” he added.
Nili Ahmadabadi stated that given the presence of antibodies in the special milk, it acts highly quickly and creates high mucosal immunity in non-infected people, noting that the product also reduces the rate of transmission of the virus in carriers and infected people.
4155/v
Source: ANA